EQRX
37 articles with EQRX
-
A new report showed the increased funding in 2021 mirrors national data that show accelerated financing in support of new therapies for multiple diseases, driven by COVID-19 concerns.
-
Clinical Catch-Up: January 17-21
1/24/2022
Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look. -
Absci Corporation inked a deal with Merck. Absci will leverage its Bionic Protein non-standard amino acid technology and AI-integrated Drug Creation Platform to create enzymes for Merck.
-
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
-
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
-
23andMe, EQRx Lead IPO Rush in 2021
12/21/2021
The year kicked off with a bang as multiple companies raced to a public listing. -
EQRx and CM Life Sciences III Announce Effectiveness of Form S-4 Registration Statement and Stockholder Meeting Details to Vote on Proposed Business Combination
12/2/2021
EQRx today announced that the U.S. Securities and Exchange Commission (“SEC”) has declared CM Life Sciences III’s registration statement on Form S-4 relating to the previously announced business combination agreement between EQRx and CM Life Sciences III effective.
-
EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference
11/29/2021
EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference.
-
EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa
11/22/2021
EQRx today announced a strategic collaboration agreement with Abdul Latif Jameel Health, part of international diversified family business Abdul Latif Jameel.
-
Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership
11/18/2021
Evotec SE and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced a collaboration to design, discover and develop new therapeutic options for patients.
-
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership
11/18/2021
EQRx to leverage Evotec’s unique data-driven integrated drug discovery and development accelerator platform; partnership aims to build up jointly owned pipeline to deliver innovative, affordable and accessible medicines to patients.
-
EQRx Launches “Remaking Medicine: On The Record” Investor Video Series
11/16/2021
EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, launched a multi-part corporate video series entitled “Remaking Medicine: On The Record.” The series is moderated by Jami Rubin, EQRx’s chief financial officer, and features EQRx senior leadership team members, board directors, investors and external advisors.
-
Many mergers took place in 2021. Here’s a look at some of the hottest life sciences SPAC merger announcements so far in 2021. Many mergers took place in 2021,
-
The life sciences industry might just be filling a bit richer this week as two major venture capital firms announced the closing of new funds.
-
EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs
10/19/2021
EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced it has signed a memorandum of understanding with the National Health Service in England.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
10/6/2021
EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Absci Corporation, the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, announced a discovery collaboration.
-
Wanting to find out what is fueling the trend, BioSpace solicited the perspectives of a couple of executives who chose the SPAC route.
-
EQRx Appoints Kathy Giusti to Board of Directors
9/27/2021
EQRx today announced the appointment of Kathy Giusti to the Company’s board of directors.
-
EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021
9/17/2021
EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced a late-breaking mini oral presentation of data from its partner CStone Pharmaceuticals’ Phase 3 GEMSTONE-301 study at the European Society for Medical Oncology Congress 2021.